Home > Insider Trading > Filing (0001140361-16-068151)

Filing Details

Accession Number:: 0001140361-16-068151
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-01 21:02:16
Reporting Period:: 2016-06-01

Filing Date:: 2016-06-01
Accepted Time:: 2016-06-01 21:02:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1358762	Reata Pharmaceuticals Inc	RETA	Pharmaceutical Preparations (2834)	113651945

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1372218	Cpmg Inc	2000 Mckinney Ave, Ste 2125 Dallas TX 75201		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2016-06-01	113	$0.00	113	No	4	C	Direct
Class A Common Stock	Acquisiton	2016-06-01	27,651	$0.00	27,651	No	4	C	Indirect	By Kestrel Fund, LP
Class A Common Stock	Acquisiton	2016-06-01	1,153	$0.00	1,153	No	4	C	Indirect	By Willet Fund, LP
Class A Common Stock	Acquisiton	2016-06-01	11,076	$0.00	11,076	No	4	C	Indirect	By CD Fund, LP
Class A Common Stock	Acquisiton	2016-06-01	13,493	$0.00	13,493	No	4	C	Indirect	By Mallard Fund, LP
Class A Common Stock	Acquisiton	2016-06-01	57,349	$0.00	57,349	No	4	C	Indirect	By Yellow Warbler, LP
Class A Common Stock	Acquisiton	2016-06-01	134	$0.00	134	No	4	C	Indirect	By Redbird Life Sciences Partners, LP
Class A Common Stock	Acquisiton	2016-06-01	56,739	$11.43	57,892	No	4	P	Indirect	By Willet Fund, LP
Class A Common Stock	Acquisiton	2016-06-01	127,691	$12.76	185,583	No	4	P	Indirect	By Willet Fund, LP
Class A Common Stock	Acquisiton	2016-06-01	8,233	$13.22	193,816	No	4	P	Indirect	By Willet Fund, LP
Class A Common Stock	Acquisiton	2016-06-01	28,797	$13.26	222,613	No	4	P	Indirect	By Willet Fund, LP
Class A Common Stock	Acquisiton	2016-06-01	6,203	$14.22	228,816	No	4	P	Indirect	By Willet Fund, LP
Class A Common Stock	Acquisiton	2016-06-01	23,890	$14.11	252,706	No	4	P	Indirect	By Willet Fund, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Indirect	By Kestrel Fund, LP
No	4	C	Indirect	By Willet Fund, LP
No	4	C	Indirect	By CD Fund, LP
No	4	C	Indirect	By Mallard Fund, LP
No	4	C	Indirect	By Yellow Warbler, LP
No	4	C	Indirect	By Redbird Life Sciences Partners, LP
No	4	P	Indirect	By Willet Fund, LP
No	4	P	Indirect	By Willet Fund, LP
No	4	P	Indirect	By Willet Fund, LP
No	4	P	Indirect	By Willet Fund, LP
No	4	P	Indirect	By Willet Fund, LP
No	4	P	Indirect	By Willet Fund, LP

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Class B common stock	Disposition	2016-06-01	113	$0.00	113	$0.00
Class A Common Stock	Class B common stock	Disposition	2016-06-01	27,651	$0.00	27,651	$0.00
Class A Common Stock	Class B common stock	Disposition	2016-06-01	1,153	$0.00	1,153	$0.00
Class A Common Stock	Class B common stock	Disposition	2016-06-01	11,076	$0.00	11,076	$0.00
Class A Common Stock	Class B common stock	Disposition	2016-06-01	13,493	$0.00	13,493	$0.00
Class A Common Stock	Class B common stock	Disposition	2016-06-01	57,349	$0.00	57,349	$0.00
Class A Common Stock	Class B common stock	Disposition	2016-06-01	134	$0.00	134	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,251	No	4	C	Direct
307,776	No	4	C	Indirect
12,826	No	4	C	Indirect
123,279	No	4	C	Indirect
150,186	No	4	C	Indirect
638,338	No	4	C	Indirect
1,490	No	4	C	Indirect

Footnotes

The Class B common stock is convertible into Class A common stock on a one-for-one basis (a) at the holder's election at any time after the date that is six months following the date of the closing of the initial public offering of the Issuer's Class A common stock, (b) at the holder's election prior to that time subject to certain conditions, or (c) at the option of the Issuer's board of directors, in its sole discretion, at any time or multiple times from time to time on or before the closing of the initial public offering. The conversion right of the Class B common stock has no expiration date.
This price reflects the weighted average purchase price for open-market purchase orders placed by the Reporting Person with its broker on May 26, 2016, within a $1.00 range. The actual prices for these transactions range from $11.06 to $11.85, inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
This price reflects the weighted average purchase price for open-market purchase orders placed by the Reporting Person with its broker on May 26, 2016, within a $1.00 range. The actual prices for these transactions range from $12.12 to $13.00, inclusive.
This price reflects the weighted average purchase price for open-market purchase orders placed by the Reporting Person with its broker on May 26, 2016, within a $1.00 range. The actual prices for these transactions range from $13.17 to $13.25, inclusive.
This price reflects the weighted average purchase price for open-market purchase orders placed by the Reporting Person with its broker on May 27, 2016, within a $1.00 range. The actual prices for these transactions range from $12.99 to $13.50, inclusive.
This price reflects the weighted average purchase price for open-market purchase orders placed by the Reporting Person with its broker on May 27, 2016, within a $1.00 range. The actual prices for these transactions range from $14.00 to $14.3099, inclusive.
This price reflects the weighted average purchase price for open-market purchase orders placed by the Reporting Person with its broker on May 31, 2016, within a $1.00 range. The actual prices for these transactions range from $13.74 to $14.48, inclusive.
Due to the conditions to closing of the initial public offering of the Class A common stock, these purchases were not deemed to occur until closing, on June 1, 2016.
The Reporting Person is the investment manager of each of the Kestrel Fund, LP, the Willet Fund, LP, the CD Fund, LP, the Mallard Fund, LP, the Yellow Warbler, LP and Redbird Life Sciences Partners. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.